NEXTBio Capital Management LP Makes New Investment in Vor Biopharma Inc. $VOR

NEXTBio Capital Management LP acquired a new position in Vor Biopharma Inc. (NASDAQ:VOR) in the 4th quarter, HoldingsChannel reports. The firm acquired 999,967 shares of the company’s stock, valued at approximately $13,080,000. Vor Biopharma makes up 7.7% of NEXTBio Capital Management LP’s portfolio, making the stock its 3rd largest position. NEXTBio Capital Management LP owned 0.10% of Vor Biopharma at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Frazier Life Sciences Management L.P. purchased a new stake in Vor Biopharma in the 4th quarter worth approximately $33,275,000. Fcpm Iii Services B.V. purchased a new stake in Vor Biopharma in the 3rd quarter worth approximately $18,496,000. UBS Group AG lifted its holdings in Vor Biopharma by 284.8% in the 4th quarter. UBS Group AG now owns 292,118 shares of the company’s stock worth $3,821,000 after buying an additional 216,209 shares during the period. Jane Street Group LLC purchased a new stake in Vor Biopharma in the 1st quarter worth approximately $140,000. Finally, Geode Capital Management LLC lifted its holdings in Vor Biopharma by 578.3% in the 4th quarter. Geode Capital Management LLC now owns 185,808 shares of the company’s stock worth $2,432,000 after buying an additional 158,416 shares during the period. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Trading Up 1.9%

VOR opened at $14.36 on Friday. The stock has a fifty day simple moving average of $15.09 and a two-hundred day simple moving average of $13.90. Vor Biopharma Inc. has a 12-month low of $3.63 and a 12-month high of $65.80.

Vor Biopharma (NASDAQ:VOR) last announced its quarterly earnings data on Monday, March 30th. The company reported $307.61 EPS for the quarter. Research analysts forecast that Vor Biopharma Inc. will post -2.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on VOR. Wedbush increased their price objective on Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a report on Monday, June 1st. HC Wainwright reiterated a “buy” rating and issued a $31.00 price objective on shares of Vor Biopharma in a report on Monday, May 18th. Wall Street Zen cut Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Wells Fargo & Company began coverage on Vor Biopharma in a report on Thursday, March 19th. They issued an “overweight” rating and a $30.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $42.25.

Insider Buying and Selling

In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 589,257 shares of the firm’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $16.59, for a total transaction of $9,775,773.63. Following the completion of the transaction, the director owned 4,555,741 shares of the company’s stock, valued at approximately $75,579,743.19. This trade represents a 11.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 3,002,903 shares of company stock worth $49,412,176 over the last ninety days. Company insiders own 0.27% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).